DexCom Business Summary

DexCom, Inc. (DXCM) operates a high-margin medical technology model centered on the design and commercialization of continuous glucose monitoring (CGM) systems. Revenue is primarily generated through a recurring consumable model, where patients and providers purchase disposable sensors and reusable transmitters, supplemented by software-as-a-service integrations with automated insulin delivery (AID) systems. The company’s business is segmented into the intensive insulin-dependent market (Type 1 and Type 2) and the rapidly growing non-insulin-using metabolic health sector, spearheaded by the over-the-counter Stelo platform and the 2026 rollout of the G7 15-day system. DexCom maintains a premium market position defined by superior clinical accuracy and interoperability, competing directly with Abbott Laboratories (FreeStyle Libre), Medtronic (Simplera), and Senseonics (Eversense). While Abbott leads in global unit volume through aggressive pricing, DexCom remains the technological leader in the high-acuity and integrated-device segments. The company is currently led by President and CEO Jake Leach, a 20-year veteran who assumed the role on January 1, 2026, after previously serving as COO and CTO. Leach succeeded Kevin Sayer, who now serves as Executive Chairman of the Board after a decade-long tenure that saw annual revenue grow from $250 million to over $4.6 billion. The executive leadership team includes Jereme Sylvain as Executive VP and CFO and Girish Naganathan as Executive CTO. DexCom was founded in 1999 by a team including Dr. John Burd and Scott Glenn. The company’s strategic direction is supported by a board featuring industry leaders such as Steven Altman and Bridgette Heller, with significant institutional backing from major shareholders including The Vanguard Group, BlackRock, and State Street, which collectively hold over 20% of the company’s equity.